For: | Aung W, Tsuji AB, Sudo H, Sugyo A, Ukai Y, Kouda K, Kurosawa Y, Furukawa T, Saga T, Higashi T. Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor. World J Gastroenterol 2017; 23(42): 7551-7562 [PMID: 29204055 DOI: 10.3748/wjg.v23.i42.7551] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v23/i42/7551.htm |
Number | Citing Articles |
1 |
Atsushi B. Tsuji, Tsuneo Saga. Cancer Drug Delivery Systems Based on the Tumor Microenvironment. 2019; : 289 doi: 10.1007/978-4-431-56880-3_13
|
2 |
Ashleigh Hull, Yanrui Li, Dylan Bartholomeusz, William Hsieh, Barry Allen, Eva Bezak. Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature. Cancers 2020; 12(2): 481 doi: 10.3390/cancers12020481
|
3 |
Le Yu, Jessica Wei, Pengda Liu. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Seminars in Cancer Biology 2022; 85: 69 doi: 10.1016/j.semcancer.2021.06.019
|
4 |
Ranjit K. Harwansh, Junainah Abd Hamid, Pranay Wal, Rohitas Deshmukh, Pratap Kumar Patra, Amin Gasmi. Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer. Current Pharmaceutical Design 2025; 31(31): 2504 doi: 10.2174/0113816128334659241223113743
|
5 |
Cédric Leroux, Georgia Konstantinidou. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers 2021; 13(4): 799 doi: 10.3390/cancers13040799
|